Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
NCT01908426
Interventional
Phase 3
Active, not recruiting
CELESTIAL
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with
placebo on overall survival in subjects with advanced hepatocellular carcinoma who have
received prior sorafenib.
Sep 26,2013
All
18 Years
N/A
18 Years
N/A
707